All currencies in US Dollar
Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocytosis diagnosed in adults, characterized by mast cell infiltration of one or more extracutaneous organs (with or without skin involvement). The identification of KIT D816V mutation and the emergence of novel targeted therapies have significantly improved the diagnosis and treatment of systemic mastocytosis. However, certain aspects of clinical care, particularly the diagnosis, assessment, and management of mediator-related symptoms continue to present challenges. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with systemic mastocytosis.
ValentPHornyHPEscribanoL. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res2001;25:603–625.
SwerdlowSHCampoEHarrisNL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition). International Agency for Research on Cancer; Lyon, France; 2017.
RyanRJAkinCCastellsM. Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications. Mod Pathol2013;26:533–543.
JawharMSchwaabJHornyHP. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis. Eur J Clin Invest2016;46:392–397.
Sanchez-MunozLMorgadoJMAlvarez-TwoseI. Diagnosis and classification of mastocytosis in non-specialized versus reference centres: a Spanish Network on Mastocytosis (REMA) study on 122 patients. Br J Haematol2016;172:56–63.
NagataHWorobecASOhCK. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A1995;92:10560–10564.
SchwaabJSchnittgerSSotlarK. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood2013;122:2460–2466.
HartmannKEscribanoLGrattanC. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol2016;137:35–45.
EscribanoLAlvarez-TwoseISanchez-MunozL. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol2009;124:514–521.
LimKHTefferiALashoTL. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood2009;113:5727–5736.
PardananiALimKHLashoTL. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood2010;115:150–151.
Alvarez-TwoseIJara-AcevedoMMorgadoJM. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol2016;137:168–178e161.
AkinCScottLMKocabasCN. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with “idiopathic” anaphylaxis. Blood2007;110:2331–2333.
PardananiAChenDAbdelrahmanRA. Clonal mast cell disease not meeting WHO criteria for diagnosis of mastocytosis: clinicopathologic features and comparison with indolent mastocytosis. Leukemia2013;27:2091–2094.
AkinC. Mast cell activation syndromes. J Allergy Clin Immunol2017;140:349–355.
LyonsJJYuXHughesJD. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet2016;48:1564–1569.
CastellsMAustenKF. Mastocytosis: mediator-related signs and symptoms. Int Arch Allergy Immunol2002;127:147–152.
BrockowKJoferCBehrendtHRingJ. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy2008;63:226–232.
van AnrooijBKluin-NelemansJCSafyM. Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis. Allergy2016;71:1585–1593.
GulenTHagglundHDahlenBNilssonG. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. J Intern Med2016;279:211–228.
ZanottiRBonadonnaPBonifacioM. Isolated bone marrow mastocytosis: an underestimated subvariant of indolent systemic mastocytosis. Haematologica2011;96:482–484.
PardananiALimKHLashoTL. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood2009;114:3769–3772.
WangSAHutchinsonLTangG. Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components. Am J Hematol2013;88:219–224.
ValentPSotlarKSperrWR. Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposal. Ann Oncol2014;25:1691–1700.
ValentPBergerJCerny-ReitererS. Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage. Ann Hematol2015;94:223–231.
ValentPSotlarKSperrWR. Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features. Leuk Res2015;39:1–5.
Georgin-LavialleSLhermitteLDubreuilP. Mast cell leukemia. Blood2013;121:1285–1295.
JawharMSchwaabJMeggendorferM. The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm. Haematologica2017;102:1035–1043.
SperrWRJordanJHFieglM. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol2002;128:136–141.
SchwartzLBMetcalfeDDMillerJS. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med1987;316:1622–1626.
SperrWREl-SamahiAKundiM. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest2009;39:914–923.
AbererESavicSBretterklieberA. Disease spectrum in patients with elevated serum tryptase levels. Australas J Dermatol2015;56:7–13.
CaugheyGH. Tryptase genetics and anaphylaxis. J Allergy Clin Immunol2006;117:1411–1414.
HornyHPSotlarKValentP. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology2010;77:169–180.
ButterfieldJHLiCY. Bone marrow biopsies for the diagnosis of systemic mastocytosis: is one biopsy sufficient?Am J Clin Pathol2004;121:264–267.
Sanchez-MunozLAlvarez-TwoseIGarcia-MonteroAC. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol2011;24:1157–1168.
ReichardKKChenDPardananiA. Morphologically occult systemic mastocytosis in bone marrow: clinicopathologic features and an algorithmic approach to diagnosis. Am J Clin Pathol2015;144:493–502.
JordanJHWalchshoferSJureckaW. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol2001;32:545–552.
HornyHPSotlarKValentP. Mastocytosis: immunophenotypical features of the transformed mast cells are unique among hematopoietic cells. Immunol Allergy Clin North Am2014;34:315–321.
TeodosioCMayadoASanchez-MunozL. The immunophenotype of mast cells and its utility in the diagnostic work-up of systemic mastocytosis. J Leukoc Biol2015;97:49–59.
EscribanoLDiaz AgustinBBravoP. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma1999;35:227–235.
SotlarKHornyHPSimonitschI. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol2004;28:1319–1325.
PardananiAKimlingerTReederT. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res2004;28:777–783.
MorgadoJMSanchez-MunozLTeodosioCG. Immunophenotyping in systemic mastocytosis diagnosis: ‘CD25 positive’ alone is more informative than the ‘CD25 and/or CD2’ WHO criterion. Mod Pathol2012;25:516–521.
ChisholmKMMerkerJDGotlibJR. Mast cells in systemic mastocytosis have distinctly brighter CD45 expression by flow cytometry. Am J Clin Pathol2015;143:527–534.
SotlarKCerny-ReitererSPetat-DutterK. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol2011;24:585–595.
ValentPSotlarKHornyHP. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma2011;52:740–744.
MorgadoJMPerbelliniOJohnsonRC. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology2013;63:780–787.
Russano de Paiva SilvaGTournierESarianLO. Prevalence of CD30 immunostaining in neoplastic mast cells: a retrospective immunohistochemical study. Medicine (Baltimore)2018;97:e10642.
MayadoATeodosioCDasilva-FreireN. Characterization of CD34(+) hematopoietic cells in systemic mastocytosis: potential role in disease dissemination. Allergy2018;73:1294–1304.
EscribanoLGarcia MonteroACNunezR. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am2006;26:535–547.
Sanchez-MunozLTeodosioCMorgadoJM. Flow cytometry in mastocytosis: utility as a diagnostic and prognostic tool. Immunol Allergy Clin North Am2014;34:297–313.
LongleyBJTyrrellLLuSZ. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet1996;12:312–314.
Garcia-MonteroACJara-AcevedoMTeodosioC. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood2006;108:2366–2372.
SotlarKColakSBacheA. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol2010;220:586–595.
TefferiALevineRLLimKH. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia2009;23:900–904.
TrainaFVisconteVJankowskaAM. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis. PLoS One2012;7:e43090.
DamajGJorisMChandesrisO. ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases. PLoS One2014;9:e85362.
JawharMSchwaabJHausmannD. Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia2016;30:2342–2350.
JawharMSchwaabJSchnittgerS. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia2016;30:136–143.
PardananiADLashoTLFinkeC. ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis. Br J Haematol2016;175:534–536.
PardananiALashoTElalaY. Next-generation sequencing in systemic mastocytosis: derivation of a mutation-augmented clinical prognostic model for survival. Am J Hematol2016;91:888–893.
PardananiAKetterlingRPBrockmanSR. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood2003;102:3093–3096.
PardananiABrockmanSRPaternosterSF. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood2004;104:3038–3045.
BohmAFodingerMWimazalF. Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance. J Allergy Clin Immunol2007;120:192–199.
ArockMSotlarKAkinC. KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia2015;29:1223–1232.
KristensenTVestergaardHMollerMB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn2011;13:180–188.
KristensenTVestergaardHBindslev-JensenC. Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis. Am J Hematol2014;89:493–498.
Jara-AcevedoMTeodosioCSanchez-MunozL. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol2015;28:1138–1149.
KristensenTVestergaardHBindslev-JensenC. Prospective evaluation of the diagnostic value of sensitive KIT D816V mutation analysis of blood in adults with suspected systemic mastocytosis. Allergy2017;72:1737–1743.
SotlarKEscribanoLLandtO. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol2003;162:737–746.
GotlibJPardananiAAkinC. International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood2013;121:2393–2401.
BareteSAssousNde GennesC. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis2010;69:1838–1841.
RossiniMZanottiRBonadonnaP. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone2011;49:880–885.
van der VeerEvan der GootWde MonchyJG. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy2012;67:431–438.
MetcalfeDDPawankarRAckermanSJ. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J2016;9:7.
MorrowJDGuzzoCLazarusG. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol1995;104:937–940.
OranjeAPMulderPGHeideR. Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis. Clin Exp Dermatol2002;27:502–506.
ButterfieldJH. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat2010;92:73–76.
van DoormaalJJvan der VeerEvan Voorst VaderPC. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions. Allergy2012;67:683–690.
DivekarRButterfieldJ. Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders. Allergy2015;70:1230–1238.
ChoCNguyenABryantKJ. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. Immun Inflamm Dis2016;4:64–69.
RaviAButterfieldJWeilerCR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha. J Allergy Clin Immunol Pract2014;2:775–778.
CardetJCAkinCLeeMJ. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother2013;14:2033–2045.
SoterNAAustenKFWassermanSI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med1979;301:465–469.
HoranRFShefferALAustenKF. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol1990;85:852–855.
TolarJTopeWDNegliaJP. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis. N Engl J Med2004;350:735–736.
TurnerPJKempASRogersMMehrS. Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. Pediatr Dermatol2012;29:222–223.
ButterfieldJH. Survey of aspirin administration in systemic mastocytosis. Prostaglandins Other Lipid Mediat2009;88:122–124.
Broesby-OlsenSVestergaardHMortzCG. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: efficacy and safety observations. Allergy2018;73:230–238.
Gonzalez de OlanoDde la Hoz CaballerBNunez LopezR. Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA). Clin Exp Allergy2007;37:1547–1555.
GulenTHagglundHDahlenBNilssonG. High prevalence of anaphylaxis in patients with systemic mastocytosis—a single-centre experience. Clin Exp Allergy2014;44:121–129.
GorskaANiedoszytkoMLangeM. Risk factors for anaphylaxis in patients with mastocytosis. Pol Arch Med Wewn2015;125:46–53.
Alvarez-TwoseIZanottiRGonzalez-de-OlanoD. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol2014;133:520–528.
GulenTLjungCNilssonGAkinC. Risk factor analysis of anaphylactic reactions in patients with systemic mastocytosis. J Allergy Clin Immunol Pract2017;5:1248–1255.
NiedoszytkoMBonadonnaPOude ElberinkJNGoldenDB. Epidemiology, diagnosis, and treatment of Hymenoptera venom allergy in mastocytosis patients. Immunol Allergy Clin North Am2014;34:365–381.
Jimenez-RodriguezTWGarcia-NeuerMAlenazyLACastellsM. Anaphylaxis in the 21st century: phenotypes, endotypes, and biomarkers. J Asthma Allergy2018;11:121–142.
ValentP. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy2014;44:914–920.
van AnrooijBvan der VeerEde MonchyJG. Higher mast cell load decreases the risk of Hymenoptera venom-induced anaphylaxis in patients with mastocytosis. J Allergy Clin Immunol2013;132:125–130.
HaeberliGBronnimannMHunzikerTMullerU. Elevated basal serum tryptase and Hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy2003;33:1216–1220.
BonadonnaPPerbelliniOPassalacquaG. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol2009;123:680–686.
RueffFPrzybillaBBiloMB. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol2009;124:1047–1054.
Alvarez-TwoseIBonadonnaPMatitoA. Systemic mastocytosis as a risk factor for severe Hymenoptera sting-induced anaphylaxis. J Allergy Clin Immunol2013;131:614–615.
CastellsMCHornickJLAkinC. Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?J Allergy Clin Immunol Pract2015;3:350–355.
Gonzalez de OlanoDAlvarez-TwoseIEsteban-LopezMI. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol2008;121:519–526.
BonadonnaPGonzalez-de-OlanoDZanottiR. Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety, and practical considerations. J Allergy Clin Immunol Pract2013;1:474–478.
VerburgMOldhoffJMKlemansRJ. Rush immunotherapy for wasp venom allergy seems safe and effective in patients with mastocytosis. Eur Ann Allergy Clin Immunol2015;47:192–196.
RueffFWenderothAPrzybillaB. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol2001;108:1027–1032.
CarterMCRobynJABresslerPB. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol2007;119:1550–1551.
WarrierPCasaleTB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol2009;102:257–258.
RossiniMZanottiROrsoliniG. Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis. Osteoporos Int2016;27:2411–2421.
MarshallAKavanaghRTCrispAJ. The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis. Br J Rheumatol1997;36:393–396.
RossiniMZanottiRViapianaO. Zoledronic acid in osteoporosis secondary to mastocytosis. Am J Med2014;127:1127e1121–1124.
LehmannTBeyelerCLammleB. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br J Rheumatol1996;35:898–900.
WeideREhlenzKLorenzW. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann Hematol1996;72:41–43.
LarocheMLivideanuCPaulCCantagrelA. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis. Am J Med2011;124:776–778.
OrsoliniGGavioliITripiG. Denosumab for the treatment of mastocytosis-related osteoporosis: a case series. Calcif Tissue Int2017;100:595–598.
KrugerAHamannCBrendelC. Multimodal therapy for vertebral involvement of systemic mastocytosis. Spine (Phila Pa 1976)2009;34:E626–628.
GotlibJKluin-NelemansHCGeorgeTI. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med2016;374:2530–2541.
ChandesrisMODamajGCanioniD. Midostaurin in advanced systemic mastocytosis. N Engl J Med2016;374:2605–2607.
DeAngeloDJGeorgeTILinderA. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia2018;32:470–478.
JawharMSchwaabJNaumannN. Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers. Blood2017;130:137–145.
Kluin-NelemansHCOldhoffJMVan DoormaalJJ. Cladribine therapy for systemic mastocytosis. Blood2003;102:4270–4276.
LimKHPardananiAButterfieldJH. Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol2009;84:790–794.
BareteSLortholaryODamajG. Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood2015;126:1009–1016.
DelaporteEPierardEWolthersBG. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br J Dermatol1995;132:479–482.
CasassusPCaillat-VigneronNMartinA. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol2002;119:1090–1097.
HauswirthAWSimonitsch-KluppIUffmannM. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res2004;28:249–257.
SimonJLortholaryOCaillat-VigneronN. Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature. Pathol Biol (Paris)2004;52:294–299.
FrostMJFerraoPTHughesTPAshmanLK. Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther2002;1:1115–1124.
AkinCBrockowKD'AmbrosioC. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol2003;31:686–692.
AkinCFumoGYavuzAS. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood2004;103:3222–3225.
ZhangLYSmithMLSchultheisB. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res2006;30:373–378.
HeinrichMCJoensuuHDemetriGD. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res2008;14:2717–2725.
Vega-RuizACortesJESeverM. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res2009;33:1481–1484.
MitalAPiskorzALewandowskiK. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol2011;86:531–535.
Alvarez-TwoseIMatitoAMorgadoJM. Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature. Oncotarget2017;8:68950–68963.
PrzepiorkaDGiraltSKhouriI. Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: review of forty cases. Am J Hematol1998;57:24–28.
NakamuraRChakrabartiSAkinC. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant2006;37:353–358.
UstunCReiterAScottBL. Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. J Clin Oncol2014;32:3264–3274.
UstunCGotlibJPopatU. Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis. Biol Blood Marrow Transplant2016;22:1348–1356.
ValentPAkinCSperrWR. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res2003;27:635–641.
MatitoAMorgadoJMAlvarez-TwoseI. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One2013;8:e76116.
ErbenPSchwaabJMetzgerothG. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis. Ann Hematol2014;93:81–88.
HoermannGGleixnerKVDinuGE. The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease. Allergy2014;69:810–813.
PardananiA. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood2013;121:3085–3094.
DewachterPCastellsMCHepnerDLMouton-FaivreC. Perioperative management of patients with mastocytosis. Anesthesiology2014;120:753–759.
HermansMAWArendsNJTGerth van WijkR. Management around invasive procedures in mastocytosis: an update. Ann Allergy Asthma Immunol2017;119:304–309.
MatitoAMorgadoJMSanchez-LopezP. Management of anesthesia in adult and pediatric mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) based on 726 anesthetic procedures. Int Arch Allergy Immunol2015;167:47–56.
GuyerACSaffRRConroyM. Comprehensive allergy evaluation is useful in the subsequent care of patients with drug hypersensitivity reactions during anesthesia. J Allergy Clin Immunol Pract2015;3:94–100.
WoidackiKZenclussenACSiebenhaarF. Mast cell-mediated and associated disorders in pregnancy: a risky game with an uncertain outcome?Front Immunol2014;5:231.
WorobecASAkinCScottLMMetcalfeDD. Mastocytosis complicating pregnancy. Obstet Gynecol2000;95:391–395.
CiachKNiedoszytkoMAbacjew-ChmylkoA. Pregnancy and delivery in patients with mastocytosis treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM). PLoS One2016;11:e0146924.
MatitoAAlvarez-TwoseIMorgadoJM. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol2011;156:104–111.
UlbrichFEngelstadterHWittauNSteinmannD. Anaesthetic management of emergency caesarean section in a parturient with systemic mastocytosis. Int J Obstet Anesth2013;22:243–246.
LeiDAkinCKovalszkiA. Management of mastocytosis in pregnancy: a review. J Allergy Clin Immunol Pract2017;5:1217–1223.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 5 | 5 | 0 |
Full Text Views | 2045 | 2045 | 256 |
PDF Downloads | 887 | 887 | 118 |
EPUB Downloads | 0 | 0 | 0 |